0G8X.LSE Immunovia AB

Healthcare Commercial Services & Supplies London Exchange
0.1978 SEK
Close of Nov 3, 2026
0.0648 0.3245
Market cap
SEK 3.86M
P/E
-
P/B
-
ROE
-349.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 0G8X.LSE undervalued?

Graham number

The Graham number of Immunovia AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Immunovia AB fundamental analysis

No fundamental analysis for Immunovia AB yet.

Immunovia AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Immunovia AB

Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Full company profile